Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.54 |
| ▸ | KAT6A | Q92794 | 10/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16739378 | 0.81 | MEN1 (0.55) | GBA1KAT6AMEN1KMT2ATSHR | |
| SCHEMBL29489599 | 0.81 | MEN1 (0.55) | GBA1KAT6AMEN1KMT2ATSHR | |
| SCHEMBL3973365 | 0.79 | EGFR (0.55) | GBA1KAT6AMEN1KMT2ACA1 | |
| SCHEMBL27176171 | 0.79 | KAT6A (0.58) | GBA1KAT6AMEN1KMT2ATSHR | |
| SCHEMBL6848738 | 0.78 | CA1 (0.60) | MEN1KMT2ACA1CA2 | |
| SCHEMBL5551864 | 0.78 | CA2 (0.45) | KAT6ACA1CA2CDK1CDK2 | |
| SCHEMBL28282283 | 0.77 | KAT6A (0.53) | GBA1KAT6AMEN1KMT2ATSHR | |
| SCHEMBL21667704 | 0.77 | MEN1 (0.46) | GBA1KAT6AMEN1KMT2ATSHR | |
| SCHEMBL3973361 | 0.77 | EGFR (0.52) | GBA1KAT6AMEN1KMT2A | |
| SCHEMBL3928657 | 0.75 | CA1 (0.67) | KAT6AMEN1KMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774212-B2 | FOR THERAPY OF VIRAL INFECTION OR AS AN ASSAY STANDARD OR REAGENT | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-08-10 | — | — | US | disclosed |